- Home
- PULM vs SNTI Comparison
PULM vs SNTI Comparison
Compare PULM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- SNTI
- Stock Information
- Founded
- PULM 2003
- SNTI 2016
- Country
- PULM United States
- SNTI United States
- Employees
- PULM N/A
- SNTI N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- SNTI Health Care
- Exchange
- PULM Nasdaq
- SNTI Nasdaq
- Market Cap
- PULM 21.0M
- SNTI 21.4M
- IPO Year
- PULM N/A
- SNTI N/A
- Fundamental
- Price
- PULM $6.11
- SNTI $4.57
- Analyst Decision
- PULM
- SNTI Strong Buy
- Analyst Count
- PULM 0
- SNTI 1
- Target Price
- PULM N/A
- SNTI $12.00
- AVG Volume (30 Days)
- PULM 40.5K
- SNTI 98.1K
- Earning Date
- PULM 11-08-2024
- SNTI 03-20-2025
- Dividend Yield
- PULM N/A
- SNTI N/A
- EPS Growth
- PULM N/A
- SNTI N/A
- EPS
- PULM N/A
- SNTI N/A
- Revenue
- PULM $10,005,000.00
- SNTI N/A
- Revenue This Year
- PULM N/A
- SNTI $11.52
- Revenue Next Year
- PULM $1.00
- SNTI $78.57
- P/E Ratio
- PULM N/A
- SNTI N/A
- Revenue Growth
- PULM 47.05
- SNTI N/A
- 52 Week Low
- PULM $1.55
- SNTI $1.52
- 52 Week High
- PULM $8.44
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- PULM 51.10
- SNTI 55.11
- Support Level
- PULM $5.95
- SNTI $3.72
- Resistance Level
- PULM $6.30
- SNTI $4.93
- Average True Range (ATR)
- PULM 0.43
- SNTI 0.46
- MACD
- PULM -0.10
- SNTI 0.04
- Stochastic Oscillator
- PULM 11.86
- SNTI 74.83
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.